España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Ascendis Pharma
ASND
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$152.43
-2.15
-1.39%
At close: -
$152.43
0.00
0.00%
After Hours: 4:00 PM EDT
Get Report
Comment
Ascendis Pharma (ASND) Forecast
News
Earnings
Ascendis Pharma (ASND) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Ascendis Pharma (NASDAQ:ASND) Stock
Ascendis Pharma Stock (NASDAQ: ASND)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, February 20, 2025
Why Is BioMarin Stock Trading Higher On Thursday?
Vandana Singh
Wednesday, February 19, 2025
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
Benzinga Insights
Tuesday, February 18, 2025
Ascendis Pharma shares are trading higher aft...
Benzinga Newsdesk
Evercore ISI Group Maintains Outperform on As...
Benzinga Newsdesk
Thursday, February 13, 2025
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
Vandana Singh
Goldman Sachs Maintains Buy on Ascendis Pharm...
Benzinga Newsdesk
JP Morgan Maintains Overweight on Ascendis Ph...
Benzinga Newsdesk
Ascendis Pharma shares are trading higher aft...
Benzinga Newsdesk
Wednesday, February 12, 2025
Ascendis Pharma shares are trading higher aft...
Benzinga Newsdesk
Ascendis Pharma Authorized To Repurchase Up T...
Benzinga Newsdesk
Ascendis Pharma Q4 2024 GAAP EPS €(0.64) Beat...
Benzinga Newsdesk
Earnings Scheduled For February 12, 2025
Benzinga Insights
Tuesday, February 11, 2025
Cantor Fitzgerald Reiterates Overweight on As...
Benzinga Newsdesk
Wednesday, January 29, 2025
JP Morgan Maintains Overweight on Ascendis Ph...
Benzinga Newsdesk
Thursday, January 23, 2025
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Benzinga Insights
Wednesday, January 15, 2025
Looking Into Ascendis Pharma's Recent Short Interest
Benzinga Insights
Monday, January 13, 2025
Reported Earlier, Ascendis Pharma Projects €3...
Benzinga Newsdesk
Tuesday, January 07, 2025
This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Avi Kapoor
UBS Initiates Coverage On Ascendis Pharma wit...
Benzinga Newsdesk
Thursday, December 19, 2024
Ascendis Pharma's YORVIPATH Now Commercially ...
Benzinga Newsdesk
Monday, December 16, 2024
Ascendis Pharma Presents New InsiGHTS Trial O...
Benzinga Newsdesk
Thursday, December 12, 2024
Ascendis Pharma Announces FDA Accepts Co's Su...
Benzinga Newsdesk
Tuesday, December 03, 2024
Peering Into Ascendis Pharma's Recent Short Interest
Benzinga Insights
Friday, November 15, 2024
TD Cowen Maintains Buy on Ascendis Pharma, Lo...
Benzinga Newsdesk
Wedbush Reiterates Outperform on Ascendis Pha...
Benzinga Newsdesk
Acendis Pharma shares are trading higher afte...
Benzinga Newsdesk
Oppenheimer Maintains Outperform on Ascendis ...
Benzinga Newsdesk
Cantor Fitzgerald Reiterates Overweight on As...
Benzinga Newsdesk
Stifel Maintains Buy on Ascendis Pharma, Rais...
Benzinga Newsdesk
Thursday, November 14, 2024
Ascendis Sees FY24 Operating Expenses ~€600M
Benzinga Newsdesk
Ascendis Pharma shares are trading lower. The...
Benzinga Newsdesk
Ascendis Q3 2024 Revenue $€57.8M Vs €48M Prio...
Benzinga Newsdesk
(ASND) - Analyzing Ascendis Pharma's Short Interest
Benzinga Insights
Earnings Scheduled For November 14, 2024
Benzinga Insights
Wednesday, November 13, 2024
A Glimpse of Ascendis Pharma's Earnings Potential
Benzinga Insights
Tuesday, November 05, 2024
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Surbhi Jain
Monday, November 04, 2024
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
Vandana Singh
If You Invested $100 In This Stock 15 Years Ago, You Would Have $5,600 Today
Benzinga Insights
Cantor Fitzgerald Reiterates Overweight on As...
Benzinga Newsdesk
Ascendis Pharma, Novo Nordisk Partner For Dev...
Benzinga Newsdesk
Wednesday, October 30, 2024
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth
Vandana Singh
Wednesday, October 23, 2024
JP Morgan Maintains Overweight on Ascendis Ph...
Benzinga Newsdesk
Monday, October 21, 2024
TD Cowen Maintains Buy on Ascendis Pharma, Ra...
Benzinga Newsdesk
Tuesday, October 08, 2024
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Benzinga Insights
3 Oversold Stocks with Big RSI Rebound Potential
MarketBeat
Monday, September 30, 2024
Ascendis Pharma Presents 3-Year Data At ASBMR...
Benzinga Newsdesk
Thursday, September 26, 2024
Looking Into Ascendis Pharma's Recent Short Interest
Benzinga Insights
Wednesday, September 25, 2024
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
Vandana Singh
Tuesday, September 24, 2024
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Benzinga Insights
Monday, September 23, 2024
B of A Securities Maintains Buy on Ascendis P...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
